ATLASTeva Pharmaceutical Industries (TEVA) Q3 2026 earnings results
Teva Pharmaceutical Industries (TEVA) reported EPS of $0.86 against an analyst estimate of $0.70: a beat of $0.16 (22.9%). The quarter ended Sep 30, 2026; the company reported on Tuesday, November 3, 2026, before the open.
Status: Confirmed · 14:37 ET, Nov 3 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Teva Pharmaceutical Industries reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountTEVA Q3 2026 results at a glance
| EPS reported | $0.86 |
|---|---|
| EPS estimate | $0.70 |
| Surprise | Beat · +$0.16 (+22.9%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 3, 2026, before the open |
| Status | Confirmed · 14:37 ET, Nov 3 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Teva Pharmaceutical Industries’s Q3 2026, a calendar-year company.
Teva Pharmaceutical Industries EPS surprise history: last 5 quarters
Teva Pharmaceutical Industries beat the EPS estimate in 4 of its last 5 reports, with an average surprise of -2.2%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.70 | $0.86 | +22.9% | Beat | – |
| Jul 29, 2026 | $0.11 | $0.02 | -81.8% | Miss | +11.8% |
| Apr 29, 2026 | $0.46 | $0.53 | +15.2% | Beat | +10.9% |
| Jan 23, 2026 | $1.61 | $1.87 | +16.2% | Beat | +1.5% |
| Nov 5, 2025 | $0.67 | $0.78 | +16.4% | Beat | +19.6% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
TEVA stock reaction to the report
TEVA moved +2.97% in the first session that reflects the report (close of Nov 2, 2026 $40.70 to close of Nov 3, 2026 $41.91).
Next TEVA earnings report
Teva Pharmaceutical Industries has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the TEVA earnings calendar.
ATLAS fair value and signal for TEVA
| Last price | $42.28 (+3.9%) |
|---|---|
| ATLAS fair value | $19.61 (range $13.66–$33.47) · price is 116% above it |
| Chance of a higher close in 1 month | 51% (normal range $39.97–$44.83) |
These are model outputs from the same valuation and calibrated model as the Teva Pharmaceutical Industries stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Teva Pharmaceutical Industries Q3 2026 earnings: frequently asked questions
Did Teva Pharmaceutical Industries beat earnings estimates for Q3 2026?
Teva Pharmaceutical Industries reported EPS of $0.86 against an analyst estimate of $0.70: a beat of $0.16 (22.9%).
When did Teva Pharmaceutical Industries report Q3 2026 results?
Teva Pharmaceutical Industries reported on Tuesday, November 3, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does TEVA beat EPS estimates?
In its last 5 reports with a recorded result, Teva Pharmaceutical Industries beat the EPS estimate 4 times; the average surprise was -2.2%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer